Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors

Caroline Marty, Cécile Saint-Martin, Christian Pecquet, Sarah Grosjean, Joseph Saliba, Céline Mouton, Emilie Leroy, Ashot S. Harutyunyan, Jean-François Abgrall, Rémi Favier, Aurélie Toussaint, Eric Solary, Robert Kralovics, Stefan N. Constantinescu, Albert Najman, William Vainchenker, Isabelle Plo, Christine Bellanné-Chantelot

Blood (2014) 123 (9): 1372–1383.

https://doi.org/10.1182/blood-2013-05-504555

Published: 2014

Includes: Supplemental data

Journal Articles

Germline JAK2 Mutations In The Kinase Domain Are Responsible For Hereditary Thrombocytosis and Are Resistant To JAK2 and HSP90 Inhibitors

Caroline Marty, Ph.D, Cecile Saint-martin, Christian Pecquet, PhD, Sarah Grosjean, Joseph Saliba, PhD Student, Celine Mouton, Leroy Emilie, Ashot S. Harutyunyan, Jean-François Abgrall, Remy Favier, Eric Solary, Robert Kralovics, PhD, Stefan N. Constantinescu, MD, PhD, Albert Najman, MD, William Vainchenker, MD, PhD, Isabelle Plo, Ph.D, Christine Bellanné-Chantelot

Blood (2013) 122 (21): 1603.

https://doi.org/10.1182/blood.V122.21.1603.1603

Published: 2013

Journal Articles

Long-Term Follow-up of 94 Families with Myeloproliferative Neoplasms: Implications of the V617F JAK2 mutation, Life Expectancy and Complication Rates

Sandra Malak, MD, Myriam Labopin, MD, Isabelle Chaumarel, MD, Cecile Saint-Martin, PhD, Christine Bellanne-Chantelot, PharmD, PhD, Albert Najman, MD

Blood (2010) 116 (21): 1978.

https://doi.org/10.1182/blood.V116.21.1978.1978

Published: 2010

Journal Articles

TET2 Mutations in Polycythemia Vera (PV) in Some Cases Follow Rather Than Precede JAK2 V617F Mutation, Are Not a Disease-Initiating Event, Affect Mainly Erythropoiesis, and Contribute to Increased Aggressivity of PV Clone.

Sabina Swierczek, PhD, Christine Bellanne-Chantelot, Donghoon Yoon, PhD, Cecile Saint-Martin, Soo Jin Kim, Albert Najman, MD, Josef T. Prchal, MD

Blood (2009) 114 (22): 3913.

https://doi.org/10.1182/blood.V114.22.3913.3913

Published: 2009

Journal Articles

Analysis of the Ten-Eleven Translocation 2 ( TET2 ) gene in familial myeloproliferative neoplasms

Cécile Saint-Martin, Gwendoline Leroy, François Delhommeau, Gérard Panelatti, Sabrina Dupont, Chloé James, Isabelle Plo, Dominique Bordessoule, Christine Chomienne, André Delannoy, Alain Devidas, Martine Gardembas-Pain, Françoise Isnard, Yves Plumelle, Olivier Bernard, William Vainchenker, Albert Najman, Christine Bellanné-Chantelot, the French Group of Familial Myeloproliferative Disorders

Blood (2009) 114 (8): 1628–1632.

https://doi.org/10.1182/blood-2009-01-197525

Published: 2009

Includes: Supplemental data

Journal Articles

Single Treatment with Rituximab Monotherapy for Low-Tumor Burden Follicular Lymphoma (FL): Survival Analyses with Extended Follow-Up (F/Up) of 7 Years.

Blood (2006) 108 (11): 486.

https://doi.org/10.1182/blood.V108.11.486.486

Published: 2006

Journal Articles

Study of V617F JAK2-Positive and JAK2-Negative Patients within 18 Families with Myeloproliferative Disorders (MPD): Disease Characteristics and Evolution, EPOR and MPL Analysis.

Christine Bellanne-Chantelot, PharmD,PhD, Myriam Labopin, M.D., Florence Bellanger, Isabelle Chaumarel, Françoise Isnard, M.D., Nicole Casadevall, M.D., William Vainchenker, M.D.,Ph.D., Gilles Thomas, M.D.,Ph.D., Albert Najman, M.D., the French Group on Familial MPD

Blood (2006) 108 (11): 672.

https://doi.org/10.1182/blood.V108.11.672.672

Published: 2006

Journal Articles

Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders

Christine Bellanné-Chantelot, Isabelle Chaumarel, Myriam Labopin, Florence Bellanger, Véronique Barbu, Claudia De Toma, François Delhommeau, Nicole Casadevall, William Vainchenker, Gilles Thomas, Albert Najman

Blood (2006) 108 (1): 346–352.

https://doi.org/10.1182/blood-2005-12-4852

Published: 2006

Journal Articles

Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol

Blood (2006) 107 (1): 397–403.

https://doi.org/10.1182/blood-2005-06-2573

Published: 2006

Journal Articles

Heterogeneous Distribution of the JAK2 Val617Phe Activating Mutation in Familial Myeloproliferative Disorders.

Christine Bellanne-Chantelot, PharmD, PhD, Myriam Labopin, MD, Isabelle Chaumarel, MD, Francois Delhommeau, MD, Gwendoline Leroy, Florence Bellanger, Gilles Thomas, MD, PhD, William Vainchenker, MD, PhD, Albert Najman

Blood (2005) 106 (11): 115.

https://doi.org/10.1182/blood.V106.11.115.115

Published: 2005

Journal Articles

Interest of NT-proBNP To Detect Chemotherapy Regimens Cardiotoxicity in Patients with Hematological Malignancies: Preliminary Results.

Gerard Dine, PhD, MD, Vincent Genty, PhD, Said Brahimi, MD, Nadia Ali Ammar, MD, William Mendes, MD, Yves Rehn, PhD, Albert Najman, MD

Blood (2005) 106 (11): 1331.

https://doi.org/10.1182/blood.V106.11.1331.1331

Published: 2005

Journal Articles

Single 4-Dose Rituximab Treatment for Low-Tumor Burden Follicular Lymphoma (FL): Survival Analyses with a Follow-Up (F/Up) of at Least 5 Years.

Blood (2004) 104 (11): 585.

https://doi.org/10.1182/blood.V104.11.585.585

Published: 2004

Journal Articles

Phenotypic Description of Familial Chronic Myeloproliferative Disorders.

Albert Najman, MD, Isabelle Chaumarel, MD, Christine Bellann-Chantelot, PharmD., Ph.D., Veronique Barbu, MD,PhD, Myriam Labopin, MD,PhD, Jean D. Rain, MD,PhD, Nicole Casadevall, MD, Bruno Varet, MD, Francis Bauters, MD, Gilles Thomas, MD,PhD

Blood (2004) 104 (11): 658.

https://doi.org/10.1182/blood.V104.11.658.658

Published: 2004

Journal Articles

Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation

Blood (2001) 97 (1): 101–106.

https://doi.org/10.1182/blood.V97.1.101

Published: 2001

Journal Articles

Prognostic factors in Waldenström macroglobulinemia: a report on 232 patients with the description of a new scoring system and its validation on 253 other patients

Pierre Morel, Mathieu Monconduit, Dominique Jacomy, Pascal Lenain, Bernard Grosbois, Christine Bateli, Thierry Facon, Isabelle Dervite, Francis Bauters, Albert Najman, Aimery de Gramont, Eric Wattel

Blood (2000) 96 (3): 852–858.

https://doi.org/10.1182/blood.V96.3.852

Published: 2000

NARROW

Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors

Germline JAK2 Mutations In The Kinase Domain Are Responsible For Hereditary Thrombocytosis and Are Resistant To JAK2 and HSP90 Inhibitors

Long-Term Follow-up of 94 Families with Myeloproliferative Neoplasms: Implications of the V617F JAK2 mutation, Life Expectancy and Complication Rates

TET2 Mutations in Polycythemia Vera (PV) in Some Cases Follow Rather Than Precede JAK2 V617F Mutation, Are Not a Disease-Initiating Event, Affect Mainly Erythropoiesis, and Contribute to Increased Aggressivity of PV Clone.

Analysis of the Ten-Eleven Translocation 2 ( TET2 ) gene in familial myeloproliferative neoplasms

Single Treatment with Rituximab Monotherapy for Low-Tumor Burden Follicular Lymphoma (FL): Survival Analyses with Extended Follow-Up (F/Up) of 7 Years.

Study of V617F JAK2-Positive and JAK2-Negative Patients within 18 Families with Myeloproliferative Disorders (MPD): Disease Characteristics and Evolution, EPOR and MPL Analysis.

Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders

Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol

Heterogeneous Distribution of the JAK2 Val617Phe Activating Mutation in Familial Myeloproliferative Disorders.

Interest of NT-proBNP To Detect Chemotherapy Regimens Cardiotoxicity in Patients with Hematological Malignancies: Preliminary Results.

Single 4-Dose Rituximab Treatment for Low-Tumor Burden Follicular Lymphoma (FL): Survival Analyses with a Follow-Up (F/Up) of at Least 5 Years.

Phenotypic Description of Familial Chronic Myeloproliferative Disorders.

Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation

Prognostic factors in Waldenström macroglobulinemia: a report on 232 patients with the description of a new scoring system and its validation on 253 other patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only